As of 2024-09-09, the EV/EBITDA ratio of Rigel Pharmaceuticals Inc (RIGL) is -23.53. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RIGL's latest enterprise value is 257.94 mil USD. RIGL's TTM EBITDA according to its financial statements is -10.96 mil USD. Dividing these 2 quantities gives us the above RIGL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.4x - 14.7x | 10.7x |
| Forward P/E multiples | 11.9x - 18.8x | 15.4x |
| Fair Price | (8.79) - (10.51) | (9.49) |
| Upside | -166.0% - -178.9% | -171.3% |
| Date | EV/EBITDA |
| 2024-09-06 | -23.53 |
| 2024-09-05 | -23.67 |
| 2024-09-04 | -23.30 |
| 2024-09-03 | -23.21 |
| 2024-08-30 | -23.72 |
| 2024-08-29 | -23.90 |
| 2024-08-28 | -22.85 |
| 2024-08-27 | -23.35 |
| 2024-08-26 | -23.74 |
| 2024-08-23 | -22.18 |
| 2024-08-22 | -21.55 |
| 2024-08-21 | -22.24 |
| 2024-08-20 | -22.24 |
| 2024-08-19 | -22.55 |
| 2024-08-16 | -21.59 |
| 2024-08-15 | -22.16 |
| 2024-08-14 | -21.36 |
| 2024-08-13 | -22.49 |
| 2024-08-12 | -20.21 |
| 2024-08-09 | -18.54 |
| 2024-08-08 | -18.89 |
| 2024-08-07 | -17.99 |
| 2024-08-06 | -17.13 |
| 2024-08-05 | -16.28 |
| 2024-08-02 | -17.72 |
| 2024-08-01 | -18.25 |
| 2024-07-31 | -19.13 |
| 2024-07-30 | -19.23 |
| 2024-07-29 | -19.18 |
| 2024-07-26 | -19.40 |
| 2024-07-25 | -19.65 |
| 2024-07-24 | -19.05 |
| 2024-07-23 | -19.05 |
| 2024-07-22 | -18.38 |
| 2024-07-19 | -17.66 |
| 2024-07-18 | -17.59 |
| 2024-07-17 | -18.76 |
| 2024-07-16 | -20.21 |
| 2024-07-15 | -19.15 |
| 2024-07-12 | -18.17 |
| 2024-07-11 | -17.59 |
| 2024-07-10 | -15.94 |
| 2024-07-09 | -15.22 |
| 2024-07-08 | -14.78 |
| 2024-07-05 | -14.64 |
| 2024-07-03 | -14.56 |
| 2024-07-02 | -15.67 |
| 2024-07-01 | -15.65 |
| 2024-06-28 | -15.35 |
| 2024-06-27 | -17.45 |